BlackRock, Inc. 13D and 13G filings for Edgewise Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX |
BlackRock Inc. BLK |
6,393,567 6.800% |
0 (Unchanged) |
Filing |
| 2024-10-22 6:06 pm Purchase |
2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX |
BlackRock Inc. BLK |
6,393,567 6.800% |
2,888,368 (+82.40%) |
Filing |
| 2024-02-07 5:09 pm Purchase |
2024-01-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
BlackRock Inc. BLK |
3,505,199 4.100% |
198,089 (+5.99%) |
Filing |
| 2024-02-02 3:57 pm Purchase |
2023-12-31 | 13G | Edgewise Therapeutics, Inc. EWTX |
BlackRock Inc. BLK |
3,307,110 5.200% |
3,307,110 (New Position) |
Filing |